Engineered blood vessel could simplify dialysis for kidney patients
Disease control
Completed
This phase 3 trial tested a lab-grown blood vessel (Human Acellular Vessel, or HAV) against the standard surgically created fistula in 242 people with end-stage kidney disease on hemodialysis. The goal was to see which option works better for providing reliable access to filter b…
Phase: PHASE3 • Sponsor: Humacyte, Inc. • Aim: Disease control
Last updated Jun 27, 2026 07:58 UTC